In a model of renal failure-induced anemia, MSC-IGF-1 co-implanted with MSCs genetically engineered to secrete erythropoietin (MSC-EPO) promoted a significant hematocrit elevation when compared to the group which received the MSC-EPO + MSC-null, with a difference of approximately 20% after 98 days. This evidence concerns the gene EPO and acute kidney injury.